Trial reportPigment cell & melanoma research2014
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
Trial report in Pigment cell & melanoma research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 34 citations in OpenAlex.
- Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Review
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- Neratinib, a pan ERBB/HER inhibitor, restores sensitivity ofFrontiers in oncology · 2024Article
- Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients.The pharmacogenomics journal · 2023Article
- Next-generation sequencing in dermatology.Frontiers in medicine · 2023Review
- A Series of BRAF- and NRAS-Driven Murine Melanoma Cell Lines with Inducible Gene Modulation Capabilities.JID innovations : skin science from molecules to population health · 2022Article
- Improved indel detection in DNA and RNA via realignment with ABRA2.Bioinformatics (Oxford, England) · 2019Article
- High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material.Scientific reports · 2019Article
- Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.The oncologist · 2018Article
- New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.Cancer research · 2018Article
- Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms.Hematology/oncology clinics of North America · 2017Review
- Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications.Haematologica · 2017Article
- Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy.BMC cancer · 2017Article
- Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.JCI insight · 2017Article
- Article
- Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Review
- Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Molecular diagnosis & therapy · 2015Article
- Molecular mechanisms of ethanol-associated oro-esophageal squamous cell carcinoma.Cancer letters · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Somatic sequencing of cancers has produced new insight into tumorigenesis, tumor heterogeneity, and disease progression, but the vast majority of genetic events identified are of indeterminate clinical significance. Here, we describe a NextGen sequencing approach to fully analyzing 248 genes, including all those of known clinical significance in melanoma. This strategy features solution capture of DNA followed by multiplexed, high-throughput sequencing and was evaluated in 31 melanoma cell lines and 18 tumor tissues from patients with metastatic melanoma. Mutations in melanoma cell lines correlated with their sensitivity to corresponding small molecule inhibitors, confirming, for example, lapatinib sensitivity in ERBB4 mutant lines and identifying a novel activating mutation of BRAF. The latter event would not have been identified by clinical sequencing and was associated with responsiveness to a BRAF kinase inhibitor. This approach identified focal copy number changes of PTEN not found by standard methods, such as comparative genomic hybridization (CGH). Actionable mutations were found in 89% of the tumor tissues analyzed, 56% of which would not be identified by standard-of-care approaches. This work shows that targeted sequencing is an attractive approach for clinical use in melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.